Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros

Medicinas Complementárias
Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Sci Rep ; 13(1): 8051, 2023 05 17.
Artículo en Inglés | MEDLINE | ID: mdl-37198253

RESUMEN

Quercetin (QR) has significant anti-respiratory syncytial virus (RSV) effects. However, its therapeutic mechanism has not been thoroughly explored. In this study, a lung inflammatory injury model caused by RSV was established in mice. Untargeted lung tissue metabolomics was used to identify differential metabolites and metabolic pathways. Network pharmacology was used to predict potential therapeutic targets of QR and analyze biological functions and pathways modulated by QR. By overlapping the results of the metabolomics and the network pharmacology analyses, the common targets of QR that were likely to be involved in the amelioration of RSV-induced lung inflammatory injury by QR were identified. Metabolomics analysis identified 52 differential metabolites and 244 corresponding targets, while network pharmacology analysis identified 126 potential targets of QR. By intersecting these 244 targets with the 126 targets, hypoxanthine-guanine phosphoribosyltransferase (HPRT1), thymidine phosphorylase (TYMP), lactoperoxidase (LPO), myeloperoxidase (MPO), and cytochrome P450 19A1 (CYP19A1) were identified as the common targets. The key targets, HPRT1, TYMP, LPO, and MPO, were components of purine metabolic pathways. The present study demonstrated that QR effectively ameliorated RSV-induced lung inflammatory injury in the established mouse model. Combining metabolomics and network pharmacology showed that the anti-RSV effect of QR was closely associated with purine metabolism pathways.


Asunto(s)
Medicamentos Herbarios Chinos , Lesión Pulmonar , Neumonía Viral , Infecciones por Virus Sincitial Respiratorio , Virus Sincitial Respiratorio Humano , Humanos , Ratones , Animales , Quercetina/farmacología , Quercetina/uso terapéutico , Farmacología en Red , Lesión Pulmonar/tratamiento farmacológico , Pulmón/metabolismo , Metabolómica/métodos , Medicamentos Herbarios Chinos/farmacología
2.
Am J Emerg Med ; 38(10): 2153-2159, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-33071103

RESUMEN

INTRODUCTION: Chinese medicine (CM) has been used to treat Novel Coronavirus 2019 (COVID-19) pneumonia in China. This meta-analysis was conducted to evaluate the clinical efficacy and safety of CM in the treatment of COVID-19 pneumonia. METHODS: Randomized controlled trials (RCTs) involving CM in the treatment of COVID-19 pneumonia were identified from Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Chinese National Knowledge Infrastructure, Chinese Biomedical Database, Wanfang Database and VIP Information Database. The methodological quality of trials was evaluated with Cochrane Hanadbook criteria, and the Cochrane Collaboration's Review Manager 5.3 software was used for meta-analysis. RESULTS: A total of 7 valid studies involving 681 patients were included. The meta-analysis exhibited in comparison to conventional treatment, CM combined with conventional treatment significantly improved clinical efficacy (RR = 1.21, 95% CI [1.08,1.36]), and significantly increased viral nucleic acid negative conversion rate (RR = 1.49, 95% CI [1.13,1.97]). CM also prominently reduced pulmonary inflammation (RR = 1.27, 95% CI [1.12,1.44]), and improved host immune function (WBC, MD = 0.92, 95% CI [0.07,1.76]; LYM, MD = 0.33, 95% CI [0.08,0.57]; LYM%, MD = 2.90, 95% CI [2.09,3.71]; CRP, MD = -12.66, 95% CI [-24.40, -0.92]). Meanwhile, CM did not increase the incidence of adverse reactions (RR = 1.17, 95% CI [0.39,3.52]). CONCLUSION: According to the allocated data, CM has demonstrated clinical efficacy and safety on COVID-19 pneumonia, which need to be confirmed by high quality, multiple-center, large sample randomized controlled trials.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Medicamentos Herbarios Chinos/uso terapéutico , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2/efectos de los fármacos , Resultado del Tratamiento
3.
Int J Pediatr Otorhinolaryngol ; 119: 79-85, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30684690

RESUMEN

OBJECTIVE: Chinese herbal medicine has been gradually used to treat pediatric adenoid hypertrophy. This meta-analysis were conducted to evaluate the clinical efficacy and safety of Chinese herbal medicine in the treatment of pediatric adenoid hypertrophy. METHODS: Randomized controlled trials involving Chinese herbal medicine in the treatment of pediatric adenoid hypertrophy were identified from Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Chinese National Knowledge Infrastructure, Chinese Biomedical Database, Wanfang Database and VIP Information Database. The methodological quality of trials was evaluated with Cochrane Handbook criteria, and the Cochrane Collaboration's Review Manager 5.3 software was used for Meta-analysis. RESULTS: A total of 13 valid articles involving 1038 patients were included. The meta-analysis showed that: Compared with western medicine treatment, Chinese herbal medicine significantly improved clinical efficacy (RR = 1.33, 95% CI [1.24,1.43]), and significantly decreased A/N ratio (MD = -0.04,95%CI [-0.05,-0.03]). Chinese herbal medicine also prominently improved the quality of life (MD = -4.77,95%CI [-8.35,-1.20]). Meanwhile, it dramatically improved snoring (MD = -0.46,95%CI [-0.62,-0.30]); mouth breathing (MD = -0.52,95%CI [-0.66,-0.39]); nasal obstruction (MD = -0.56,95%CI [-0.68,-0.45]). CONCLUSION: Chinese herbal medicine has good clinical efficacy and safety on pediatric adenoid hypertrophy, which need to be confirmed by high quality, multiple-centre, large sample randomized controlled trials.


Asunto(s)
Tonsila Faríngea/patología , Medicamentos Herbarios Chinos/uso terapéutico , Calidad de Vida , Niño , Medicamentos Herbarios Chinos/efectos adversos , Humanos , Hipertrofia/complicaciones , Hipertrofia/tratamiento farmacológico , Respiración por la Boca/tratamiento farmacológico , Respiración por la Boca/etiología , Obstrucción Nasal/tratamiento farmacológico , Obstrucción Nasal/etiología , Ronquido/tratamiento farmacológico , Ronquido/etiología , Resultado del Tratamiento
4.
Artículo en Inglés | MEDLINE | ID: mdl-29849708

RESUMEN

OBJECTIVE: To confirm the effect and safety of Xiao'er Biantong (XEBT) granules for treating chronic constipation in children. METHODS: This randomized, double-blind, multicenter study enrolled 480 children with age of 1-14 years who had FC. All of them were randomly assigned to receive either XEBT granules or its placebo in the ratio of 3 : 1. The primary efficacy outcome was the frequency of spontaneous bowel movements (SBM) for 14 days, and secondary outcomes were effectual time, score of main symptoms, effect of constipation, disappearance rate of accompanying symptoms, and recurrence rate. We also observed the adverse event (AE) and adverse drug reaction (ADR) to evaluate safety. RESULTS: The sociodemographic characteristics and efficiency data were comparable in the two groups at baseline. The mean values of SBM for 14 days were 8.89 and 5.63 in the XEBT group and the placebo group, respectively, and there were 86.87% and 30.91% subjects in two groups up to SBM ≥ 3/week, respectively. There were significant differences between the two groups. The effects in the XEBT group on median effectual time of defecation, main symptom score, disappearance rate of symptoms, and the differences were significant. The conclusions based on full analysis set (FAS) and per protocol set (PPS) were consistent. Nine AEs were reported, of which 7 were in the XEBT group (2.02%) while 2 were in the placebo group (1.77%). There were no significant differences in the occurrence rate of AE and ADR between the two groups. CONCLUSIONS: Xiao'er Biantong granules have superior efficacy compared to the placebo for the treatment of functional constipation in children and are well tolerated.

6.
Zhongguo Zhong Yao Za Zhi ; 42(8): 1455-1466, 2017 Apr.
Artículo en Chino | MEDLINE | ID: mdl-29071847

RESUMEN

Acute upper respiratory tract infection is the most common infectious disease in children's respiratory system. The pathogen to the main virus, can account for more than 90% of the primary upper respiratory tract infectio. However, there is no specific anti-viral drugs specifically for the disease, in addition to the existence of excessive, widespread use or even abuse of antibiotics.Long-term clinical practice has confirmed that Chinese medicine is safe and effective in treating acute upper respiratory tract infection in children. The author reviews the literatures of multiple databases, and analyzes the advantages of Chinese patent medicine in the treatment of acute upper respiratory tract infection in children from the perspective of clinical research and experimental basic research. It also puts forward the existing problems and possible research directions of Chinese patent medicine in the treatment of acute upper respiratory tract infection in children.


Asunto(s)
Medicina Tradicional China , Infecciones del Sistema Respiratorio/terapia , Enfermedad Aguda , Niño , Humanos
7.
Chin J Integr Med ; 2016 Apr 13.
Artículo en Inglés | MEDLINE | ID: mdl-27081000

RESUMEN

OBJECTIVE: To investigate if Areca catechu L. treatment could ameliorate depressive symptoms and cognitive decline by facilitating myelination processes in prefrontal cortex. METHODS: A mouse model of cuprizoneinduced demyelination was used to mimic demyelinating disease. Two concentrations of A. catechu nut extract (ANE; 1% and 2%) were administered orally in the diet for 8 weeks. Depressive symptoms and cognition-associated behaviors were evaluated in tests of locomotor activity, tail suspension, and forced swimming; spatial memory was tested with the Y-maze. Expression of myelin basic protein (MBP), 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase), glutathione S-transferases pi (GSTpi), brain-derived neurotrophic factor (BDNF), and the transcription factor cyclic adenosine monophosphate (cAMP) response element-binding (CREB) were evaluated by western blot. RESULTS: Animals subjected to demyelination showed hyperactivity (P<0.01), impaired spatial memory (P<0.01), and depressive behaviors (P<0.05). Internally, they displayed signifificant myelin damage in the cortex, lower expression of CNPase and GSTpi, slightly decreased BDNF (P>0.05), and signifificantly reduced p-CREB (P<0.05). Nevertheless, ANE treatment demonstrated signifificant anti-depressant activity and enhancement of working memory (P<0.05 or 0.01). In addition, ANE treatment increased MBP, CNPase and GSTpi protein expression in prefrontal cortex (P<0.05). Concomitant with increased BDNF production (P<0.05), ANE treatment up-regulated phosphorylated CREB, but without statistical signifificance (P>0.05). CONCLUSION: ANE treatment might ameliorate depressive symptoms and cognitive decline by facilitating myelination processes in prefrontal cortex via induction of BDNF-CREB activation.

8.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 35(5): 559-62, 2015 May.
Artículo en Chino | MEDLINE | ID: mdl-26159019

RESUMEN

OBJECTIVE: To detect the expression of the peripheral blood P2X5 receptor at various ambient temperatures, and to explore its relationship with deficiency-cold syndrome and deficiency-heat syndrome. METHODS: Subjects were selected by questionnaire and expert diagnosis, and assigned to the normal control group, the deficiency-cold syndrome group, and the deficiency-heat syndrome group, 20 in each group. 5 mL venous blood was collected at room temperature (25 °C) and cold temperature (-4-5 °C) respectively. Then the expression of P2X5 receptor was relatively quantified by real-time fluorescence quantitative PCR, and compared at room temperature and cold temperature respectively. RESULTS: The expression of P2X5 receptor in deficiency-cold syndrome and deficiency-heat syndrome groups was lower than that in the normal control group at room temperature (P < 0.05). It decreased more at cold temperature in the deficiency-cold syndrome group than in the normal control group (P < 0.01) as well as in the deficiency-heat syndrome group (P < 0.05). The expression of P2X5 receptor showed no difference in all groups at two different temperatures (P > 0.05). CONCLUSIONS: The expression of P2X5 receptor was different in different syndrome groups at various ambient temperatures. Ambient temperatures had insignificant effect on the expression of P2X5 receptor of the population with the same syndrome.


Asunto(s)
Medicina Tradicional China , Receptores Purinérgicos P2X5/metabolismo , Frío , Calor , Humanos , Síndrome
9.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 35(4): 434-7, 2015 Apr.
Artículo en Chino | MEDLINE | ID: mdl-26043566

RESUMEN

OBJECTIVE: To explore activity laws of mitochondrial complex II in patients of deficiency-cold syndrome (DCS) and deficiency-heat syndrome (DHS) under various ambient temperatures. METHODS: Subjects were recruited by questionnaire and expert diagnosis from grade 1 - 3 undergraduates at Henan College of Traditional Chinese Medicine in November 2012, and assigned to a normal control group, the DCS group, and the DHS group, 20 in each group. Their venous blood samples were collected at two different temperature conditions. Activities of mitochondrial complex II were measured by spectrophotometry. RESULTS: (1) Comparison of mitochondrial complex It under various ambient temperatures: Compared with room temperature in the same group, activity values were all increased in the normal control group at cold temperature with significant difference (P <0.05), but there was no significant difference in the DCS group and the DHS group (P >0. 05). Compared with the normal control group, activity values of complex H were reduced in the DCS group at cold and room temperatures with significant difference (P <0.05). Compared with the DCS group, activity values of complex It were increased in the DHS group with significant difference (P <0. 05). (2) Changes of adjustment rates: Compared with room temperature, the adjustment rate all rose at cold temperature in the normal control group and the DHS group with significant difference (P <0.05), but with no significant difference found in the DCS group (P >0. 05). Compared with the normal control group at the same temperature, the adjustment rate in the DHS group and the DCS group was all reduced at cold and room temperatures with significant difference (P <0. 05). There were no significant difference in the adjustment rate between the DHS group and the DCS group (P > 0. 05). CONCLUSIONS: Environment temperature can affect the activity of mitochondrial complex II with different influence degrees on different syndrome types of people, but its change trend are basically identical.


Asunto(s)
Complejo II de Transporte de Electrones/metabolismo , Medicina Tradicional China , Frío , Calor , Humanos , Síndrome , Temperatura
10.
BMC Complement Altern Med ; 13: 367, 2013 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-24364897

RESUMEN

BACKGROUND: Community-acquired pneumonia in children is common in China. To understand current clinical characteristics and practice, we conducted a cross-sectional study to analyze quality of care on childhood pneumonia in eight eastern cities in China. METHODS: Consecutive hospital records between January 1, 2010 and December 31, 2010 were collected from 13 traditional Chinese medicine (TCM) and western medicine (WM) hospitals in February, May, August, and November (25 cases per season, 100 cases over the year), respectively. A predesigned case report form was used to extract data from the hospital medical records. RESULTS: A total of 1298 cases were collected and analyzed. Symptoms and signs upon admission at TCM and WM hospitals were cough (99.3% vs. 98.6%), rales (84.8% vs. 75.0%), phlegm (83.3% vs. 49.1%), and fever (74.9% vs. 84.0%) in frequency. Patients admitted to WM hospitals had symptoms and signs for a longer period prior to admission than patients admitted to TCM hospitals. Testing to identify etiologic agents was performed in 1140 cases (88.4%). Intravenous antibiotics were administered in 99.3% (595/598) of cases in TCM hospitals and in 98.6% (699/700) of cases in WM hospitals. Besides, Chinese herbal extract injection was used more frequently in TCM hospitals (491 cases, 82.1%) than in WM hospitals (212 cases, 30.3%) (p < 0.01). At discharge, 818 cases (63.0%) were clinically cured, with a significant difference between the cure rates in TCM (87.6%) and WM hospitals (42.0%) (OR = 9.8, 95% confidence interval (CI): 7.3 ~ 12.9, p < 0.01). Pathogen and previous medical history were more likely associated with the disappearance of rales (OR = 7.2, 95% CI: 4.8 ~ 10.9). Adverse effects were not reported from the medical records. CONCLUSIONS: Intravenous use of antibiotics is highly prevalent in children with community-acquired pneumonia regardless of aetiology. There was difference between TCM and WM hospitals with regard to symptom profile and the use of antibiotics. Intravenous use of herbal injection was higher in TCM hospitals than in WM hospitals. Most of the cases were diagnosed based on clinical signs and symptoms without sufficient confirmation of aetiology. Audit of current practice is urgently needed to improve care.


Asunto(s)
Infecciones Comunitarias Adquiridas/epidemiología , Hospitalización/estadística & datos numéricos , Medicina Tradicional China/métodos , Neumonía Bacteriana/epidemiología , Adolescente , Antibacterianos/uso terapéutico , Niño , Preescolar , China , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/microbiología , Estudios Transversales , Medicamentos Herbarios Chinos/uso terapéutico , Femenino , Hospitales , Humanos , Lactante , Masculino , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/microbiología , Resultado del Tratamiento
11.
Zhong Xi Yi Jie He Xue Bao ; 10(8): 911-7, 2012 Aug.
Artículo en Chino | MEDLINE | ID: mdl-22883408

RESUMEN

OBJECTIVE: To study the effects of Xifeng Capsule, a compound traditional Chinese herbal medicine, combined with carbamazepine on spontaneous epileptic seizure induced by lithium and pilocarpine in rats and the expression level of multidrug resistance-associated protein 1 (MRP1). METHODS: Lithium and pilocarpine were used to induce epilepsies in rats. All epileptic rats were randomly divided into model, high-dose Xifeng Capsule, medium-dose Xifeng Capsule, low-dose Xifeng Capsule, high-dose Xifeng Capsule plus carbamazepine (CBZ) (combined high-dose group), high-dose Xifeng Capsule plus half dose of CBZ (combined low-dose group) and CBZ groups with 10 rats in each group. And another 10 normal rats served as control. After treating 28 d, immunohistochemical method was used to detect the MRP1 expression in cortex and hippocampus of the epileptic rats. RESULTS: MRP1 expression in hippocampus of the treated groups was higher than that of the normal control group, with wider range and darker positive particles, but was lower than that of the model group. In the cortical areas, the differences between the combined high-dose group or the combined low-dose group and the model group were statistically significant (P<0.05). Regardless of the hippocampus CA1, CA3, gyrus or cortical areas, the influence of high-dose Xifeng Capsule on MRP1 distribution was superior to that of low-dose Xifeng Capsule; Xifeng Capsule combined with CBZ had better effects than low-dose Xifeng Capsule, medium-dose Xifeng Capsule and CBZ used alone (P<0.05). CONCLUSION: Xifeng Capsule used alone or combined with CBZ can effectively inhibit MRP1 expression in hippocampus and cortex of epileptic rats.


Asunto(s)
Corteza Cerebral/metabolismo , Medicamentos Herbarios Chinos/farmacología , Epilepsia/metabolismo , Hipocampo/metabolismo , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Animales , Epilepsia/inducido químicamente , Compuestos de Litio/efectos adversos , Masculino , Pilocarpina/efectos adversos , Ratas , Ratas Sprague-Dawley
12.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 30(4): 416-8, 2010 Apr.
Artículo en Chino | MEDLINE | ID: mdl-20669682

RESUMEN

OBJECTIVE: To observe the changes of free radicals in rats after ovariectomy and the intervention effect of fetal renal cell suspension (FRCS) on them. METHODS: Totally 48 Sprague-Dawley rats, eight in the normal control group were sham-operated and treated with saline; the other 40 were ovariectomized and randomly divided into four groups: the model control group (A) administered with normal saline, the positive control group (B) administered with nilestriol, the two testing groups (C and D) administered respectively with living and dead FRCS. The administration was beginning from 12 weeks after operation and lasted for four weeks. Levels of serum superoxide dismutase (SOD) and nitric monoxide synthase (NOS) activity, malondialdehyde (MDA) and nitric oxide (NO) contents were measured at the terminal of the study. RESULTS: Compared with the sham-operated group, levels of SOD, NOS and NO in Group A were significantly lower, while level of MDA was significantly higher (P < 0.01). Compared with Group A, all above-mentioned abnormalities of indices were inversely changed in the three intervened groups significantly (P < 0.05 or P < 0.01), but showed insignificant difference in the paired comparisons of the three groups (P > 0.05). CONCLUSION: High free radical condition is surely present in ovariectomized rats, FRCS can lessen the injury of free radicals and enhance the oxidation antagonizing capacity of the organism.


Asunto(s)
Radicales Libres/metabolismo , Riñón/citología , Ovariectomía , Animales , Células Cultivadas , Femenino , Riñón/embriología , Malondialdehído/metabolismo , Óxido Nítrico/metabolismo , Ratas , Ratas Sprague-Dawley , Superóxido Dismutasa/metabolismo
13.
Biochem Cell Biol ; 88(4): 655-63, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20651837

RESUMEN

Venlafaxine, a novel antidepressant, inhibits serontonin and norepinephrine reuptake in the presynaptic cleft. Unlike typical selective serontonin reuptake inhibitors (SSRIs), venlafaxine may have modulatory effects on nerve terminals and neuronal plasticity. Our preliminary data found that 5 mg.kg-1.d-1 of venlafaxine treatment prevented decreased synaptophysin (SYP) in the hippocampus, which results from chronic restrained stress in the rat model. The present study investigates whether venlafaxine regulates alterations of synaptophysin and neuronal cell adhesion molecule (NCAM) in a post-stroke depression mouse model. We compared the expression level of SYP and NCAM in the hippocampus of global cerebral ischemic (GCI) mice treated with different doses of venlafaxine using immunohistological and Western blot analysis. Pre-treatment with intraperitoneal injection of venlafaxine (2.5 and 5.0 mg.kg-1.d-1) for 14 days significantly prevented the decrease of SYP in the hilus area of the hippocampus in vehicle-treated GCI mice. NCAM was significantly higher in the hippocampus of vehicle-treated GCI mice, and pretreatment with venlafaxine prevented alterations of NCAM, with the high-dose venlafaxine group comparable with vehicle-sham mice. The results suggest the alteration of neuronal remodeling proteins in the hippocampus may be an underlying mechanism of venlafaxine in treating post-stroke depression.


Asunto(s)
Isquemia Encefálica/metabolismo , Ciclohexanoles/farmacología , Hipocampo/metabolismo , Molécula L1 de Adhesión de Célula Nerviosa/metabolismo , Sinaptofisina/metabolismo , Animales , Antidepresivos de Segunda Generación/farmacología , Isquemia Encefálica/complicaciones , Isquemia Encefálica/patología , Trastorno Depresivo/etiología , Trastorno Depresivo/metabolismo , Trastorno Depresivo/patología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Hipocampo/patología , Masculino , Ratones , Plasticidad Neuronal/efectos de los fármacos , Plasticidad Neuronal/fisiología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Factores de Tiempo , Clorhidrato de Venlafaxina
14.
Chin J Integr Med ; 16(5): 430-4, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20535583

RESUMEN

OBJECTIVE: To observe the effect of matrine on human ether à go-go related gene (HERG) potassium channels expressed in Chinese hamster ovary (CHO) cells and investigate whether HERG channel is a new target of the pharmacological effect of matrine on arrhythmia and tumor METHODS: HERG channel potassium current in CHO cell was recorded using whole-cell patch-clamp technique, and the influence of matrine on the current was explored. RESULTS: Matrine inhibited HERG potassium current in a dose-dependent manner, and the 50% inhibitory concentration (IC IC(50)) was 411±23 µmol/L. Matrine had no significant effect on the activation kinetics, and mainly blocked HERG channels in their closed state. CONCLUSIONS: The blocking effect of matrine on HERG channels might be one of the mechanisms against arrythmias and tumors. Unlike most other blockers exerting blocking effect at the intracellular sites by entering the cell with the opening of HERG channel, matrine blocked HERG channels at the extracellular sites.


Asunto(s)
Alcaloides/farmacología , Canales de Potasio Éter-A-Go-Go/genética , Quinolizinas/farmacología , Animales , Células CHO , Cricetinae , Cricetulus , Canal de Potasio ERG1 , Canales de Potasio Éter-A-Go-Go/metabolismo , Humanos , Matrinas
15.
Clin Exp Pharmacol Physiol ; 36(10): 963-8, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19413596

RESUMEN

1. Pirfenidone (PFD; 5-methyl-1-phenyl-2(1H)-pyridone) is an effective and novel agent with antifibrotic and anti-inflammatory properties. In the present study, we investigated the antifibrotic effects of PFD on experimental liver fibrosis models in rodents and the possible underlying molecular mechanisms. 2. Liver fibrosis was induced by carbon tetrachloride (CCl(4)) in BALB/c mice. Pirfenidone (250 mg/kg) and silymarin (50 mg/kg) were given to different groups of rats by gastric gavage for 4 weeks. Pirfenidone significantly attenuated fibrosis severity, as determined by histopathological scores and hydroxyproline levels in liver tissue, by 49.8 and 44.9%, respectively, compared with the CCl(4)-treated group. The antifibrotic effects of PFD were significantly greater than those of silymarin, as indicated by a decrease of 23.5 and 24.8% in histopathological scores and hydroxyproline levels, respectively. 3. Liver fibrosis was also induced by albumin antigen-antibody complex in Wistar rats, which were then treated with the same doses of PFD and silymarin for 8 weeks. Pirfenidone significantly reduced the degree of fibrosis compared with CCl(4)-treated rats (by 45.0 and 51.0% as determined by histopathological scores and hydroxyproline levels in liver tissue, respectively). The antifibrotic effects of PFD were comparable to those of silymarin. 4. The effects of PFD on the expression of extracellular matrix-associated genes in human hepatic stellate cells (the LX-2 cell line) were measured by real-time quantitative polymerase chain reaction. LX-2 cells were treated with or without 100 micromol/L or 1 mmol/L PFD for 24 h. Pirfenidone significantly inhibited the expression of a-smooth muscle actin and Type I collagen in 8 ng/mL transforming growth factor-beta1- or 5% fetal bovine serum-activated LX-2 cells in a dose-dependent manner. 5. In conclusion, the results of the present study demonstrate that PFD is effective in ameliorating fibrogenesis induced by CCl(4) in mice and by the albumin complex in rats. These effects were mediated mainly via inhibition of the activation of hepatic stellate cells, as well as antifibrotic actions (i.e. inhibition of collagen synthesis) of PFD.


Asunto(s)
Albúminas , Tetracloruro de Carbono , Células Estrelladas Hepáticas/efectos de los fármacos , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/prevención & control , Piridonas/uso terapéutico , Albúminas/inmunología , Animales , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Complejo Antígeno-Anticuerpo , Células Cultivadas , Citoprotección/efectos de los fármacos , Antagonismo de Drogas , Evaluación Preclínica de Medicamentos , Femenino , Células Estrelladas Hepáticas/metabolismo , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Piridonas/farmacología , Ratas , Ratas Wistar
17.
Zhonghua Yi Xue Za Zhi ; 86(36): 2563-6, 2006 Sep 26.
Artículo en Chino | MEDLINE | ID: mdl-17198567

RESUMEN

OBJECTIVE: To investigate the antifibrotic effects of silymarin on hepatic fibrosis. METHODS: Sixty-one male Wistar rats were randomly divided into three groups: control group (15 rats); DMN model group (23 rats), injected intraperitoneally with dimethylnitrosamine (DMN) 10 mg/kg twice per week for 8 weeks to induce hepatic fibrosis; and silymarin group (23 rats), injected intraperitoneally with DMN and given silymarin 50 mg/kg by gastric gavage daily for 8 weeks. Eight weeks late all rats were sacrificed. Blood samples were collected to measure the alanine transaminase (ALT), aspirate aminotransferase (AST), albumin, and total bilirubin (TBIL). The hydroxyproline (Hyp) content in the liver tissue was measured. The histopathological changes as well as the fibrosis stages and score were examined by microscopy. RESULTS: The levels of ALT, AST, and TBIL of the silymarin groups were 59 U/L +/- 19 U/L, 159 U/L +/- 39 U/L, and mean rank 24 respectively, all significantly lower than those of the DMN model group (128 U/L +/- 25 U/L, 246 U/L +/- 61 U/L, and mean rank 37 respectively, P < 0.01, P = 0.001, and P = 0.003). Compared with DMN rats, the level of Hyp of the silymarin was lower by 42.6%, the hepatic score of the silymarin was 6.2 +/- 2.4, significantly than that of the DMN model group (12.8 +/- 4.4, P = 0.001), and more cases in the silymarin group were at the lower stages. CONCLUSION: Silymarin markedly inhibits and reverse the progression of hepatic fibrosis induced by dimethylnitrosamine.


Asunto(s)
Cirrosis Hepática Experimental/tratamiento farmacológico , Silimarina/uso terapéutico , Alanina Transaminasa/sangre , Animales , Aspartato Aminotransferasas/sangre , Bilirrubina/sangre , Dimetilnitrosamina , Hidroxiprolina/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/fisiopatología , Cirrosis Hepática Experimental/sangre , Cirrosis Hepática Experimental/inducido químicamente , Pruebas de Función Hepática , Masculino , Sustancias Protectoras/farmacología , Sustancias Protectoras/uso terapéutico , Distribución Aleatoria , Ratas , Ratas Wistar , Albúmina Sérica/metabolismo , Silimarina/farmacología
18.
Neuropsychopharmacology ; 28(1): 53-62, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12496940

RESUMEN

It has been proposed that antidepressants have neuroprotective effects on hippocampal neurons. To further test this hypothesis, brain-derived neurotrophic factor (BDNF), B cell lymphoma protein-2 (Bcl-2), and copper-zinc superoxide dismutase (Cu/Zn-SOD) were examined immunohistochemically in hippocampal neurons of Sprague-Dawley rats following daily treatment with 5 or 10 mg/kg of amitriptyline or venlafaxine for 21 days. At 5 mg/kg, both amitriptyline and venlafaxine increased the intensity of BDNF immunostaining in hippocampal pyramidal neurons, and the intensity of Bcl-2 immunostaining in hippocampal mossy fibers, but did not alter the Cu/Zn-SOD immunoreactivity. The high dose of venlafaxine, however, decreased the intensity of BDNF immunostaining in all subareas of the hippocampus and increased the intensity of Cu/Zn-SOD immunostaining in the dentate granular cell layer. The high dose of amitriptyline increased the intensity of Cu/Zn-SOD immunostaining, but did not affect the immunoreactivity of Bcl-2 or BDNF. These findings suggest that the chronic administration of amitriptyline or venlafaxine at 5 mg/kg, but not 10 mg/kg, may be neuroprotective to hippocampal neurons. These dose-related effects of antidepressant drugs on hippocampal neurons may have relevance to disparate findings in the field.


Asunto(s)
Antidepresivos/farmacología , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Hipocampo/metabolismo , Fármacos Neuroprotectores/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Superóxido Dismutasa/metabolismo , Amitriptilina/farmacología , Animales , Antidepresivos Tricíclicos/farmacología , Ciclohexanoles/farmacología , Densitometría , Relación Dosis-Respuesta a Droga , Hipocampo/efectos de los fármacos , Hipocampo/enzimología , Inmunohistoquímica , Masculino , Ratas , Ratas Sprague-Dawley , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Clorhidrato de Venlafaxina , Aumento de Peso/efectos de los fármacos
19.
Zhongguo Zhong Yao Za Zhi ; 27(3): 211-5, 2002 Mar.
Artículo en Chino | MEDLINE | ID: mdl-12774405

RESUMEN

OBJECTIVE: To acquire a deep understanding of the possible mechanisms of realgar in the treatment of acute promyelocytic leukemia (APL). METHOD: All-trans retinoic acid (ATRA) resistant APL cell line MR2 was used as in vitro model. The effect of realgar on MR2 cell was observed by watching cell viability, cell growth, and by using Methy thiazolyl tetrazolium (MTT) assay, cell morphology, DNA gel electrophoresis and flow cytometry assay. RESULT: The viability and growth of MR2 cell were inhibited after the treatment, to some extent, in a dose and time dependent manner. After being treated with realgar, MR2 cell presented morphologically some features of apoptotic cells such as intact cell membrane, chromatin condensation and nuclear fragmentation, and apoptotic body could be found by electron microscopy as well. Sub-G1 cells were observed by flow cytometry, as well as Annexin V FITC+/PI-cells. DNA ladder could be found by DNA gel electrophoresis. CONCLUSION: Realgar can induce apoptosis of ATRA resistant APL cell line MR2, Which shows the therapeutic effect of realgar on APL may be different from that of ATRA.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Arsenicales/farmacología , Resistencia a Antineoplásicos , Leucemia Promielocítica Aguda/patología , Sulfuros/farmacología , Tretinoina/farmacología , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Humanos , Materia Medica/farmacología , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA